Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

被引：364

作者：

Torres, VE ^{[1
]}

Wang, XF

Qian, Q

Somlo, S

Harris, PC

Gattone, VH

机构：

[1] Mayo Clin, Coll Med, Div Nephrol, Rochester, MN 55905 USA

[2] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06536 USA

[3] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA

来源：

NATURE MEDICINE | 2004年 / 10卷 / 04期

关键词：

D O I：

10.1038/nm1004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2(-/tm1Som)), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.

引用

页码：363 / 364

页数：2

共 14 条

[1] Functional properties of Ca2+-inhibitable type 5 and type 6 adenylyl cyclases and role of Ca2+ increase in the inhibition of intracellular cAMP content [J].

Chabardès, D ;

Imbert-Teboul, M ;

Elalouf, JM .

CELLULAR SIGNALLING, 1999, 11 (09) :651-663

[2] THE CLINICAL UTILITY OF RENAL CONCENTRATING CAPACITY IN POLYCYSTIC KIDNEY-DISEASE [J].

GABOW, PA ;

KAEHNY, WD ;

JOHNSON, AM ;

DULEY, IT ;

MANCOJOHNSON, M ;

LEZOTTE, DC ;

SCHRIER, RW .

KIDNEY INTERNATIONAL, 1989, 35 (02) :675-680

[3] Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist [J].

Gattone, VH ;

Wang, XF ;

Harris, PC ;

Torres, VE .

NATURE MEDICINE, 2003, 9 (10) :1323-1326

[4] Polycystin-2 is an intracellular calcium release channel [J].

Koulen, P ;

Cai, YQ ;

Geng, L ;

Maeda, Y ;

Nishimura, S ;

Witzgall, R ;

Ehrlich, BE ;

Somlo, S .

NATURE CELL BIOLOGY, 2002, 4 (03) :191-197

[5] Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells [J].

Nauli, SM ;

Alenghat, FJ ;

Luo, Y ;

Williams, E ;

Vassilev, P ;

Lil, XG ;

Elia, AEH ;

Lu, WN ;

Brown, EM ;

Quinn, SJ ;

Ingber, DE ;

Zhou, J .

NATURE GENETICS, 2003, 33 (02) :129-137

[6] Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells [J].

Qian, Q ;

Hunter, LW ;

Li, M ;

Marin-Padilla, M ;

Prakash, YS ;

Somlo, S ;

Harris, PC ;

Torres, VE ;

Sieck, GC .

HUMAN MOLECULAR GENETICS, 2003, 12 (15) :1875-1880

[7] Phenotypic analysis of conditionally immortalized cells isolated from the BPK model of ARPKD [J].

Sweeney, WE ;

Kusner, L ;

Carlin, CR ;

Chang, S ;

Futey, L ;

Cotton, CU ;

Dell, KM ;

Avner, ED .

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 281 (05) :C1695-C1705

[8] The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists [J].

Thibonnier, M ;

Coles, P ;

Thibonnier, A ;

Shoham, M .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :175-202

[9]

VERANI RR, 1988, MODERN PATHOL, V1, P457

[10] cAMP-dependent fluid secretion in rat inner medullary collecting ducts [J].

Wallace, DP ;

Rome, LA ;

Sullivan, LP ;

Grantham, JJ .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2001, 280 (06) :F1019-F1029

← 1 2 →